Field bean protease inhibitor preparations, unlike methotrexate, can completely suppress Yoshida sarcoma tumor in rats.
Protease inhibitor preparations (PIP) with antitryptic and antichymotryptic activities, isolated from field bean legume as well as doxorubicin and cyclophosphamide could effectively suppress the growth of Yoshida sarcoma ascites tumor cells transplanted in adult rats and prevent their death. As against this, methotrexate and heat-inactivated PIP were ineffective in such rats at varied doses of treatment tried. The percent survival of animals appeared to be related to the purity, treatment mode and the dose of PIP used. Zymographic analysis of the trypsin activated sarcoma cell homogenate revealed the presence of six protease bands in the molecular weight range of 51kD to 206kD. Prolonged interactions of such zymograms with protease inhibitors such as 20mM EDTA or 5mM diisopropyl flurophosphate (DIFP) or 400 micrograms/ml of PIP in reaction buffer indicated that these are not metalloproteases but serine proteases whose activities are inhibited by PIP and DIFP. Since proteases are involved in cell growth regulation and cell transformation, we hypothesize a positive relationship between the field bean protease inhibitor's blocking action on tumor cell proteases and its tumor suppressing activity.
Banerji
A P
AP
Department of Biological Chemistry, Tata Memorial Centre, Parel, Bombay, India.
Fernandes
A O
AO
D000818:Animals; D000972:Antineoplastic Agents, Phytogenic / Q000627:therapeutic use*; D003520:Cyclophosphamide / Q000627:therapeutic use; D004317:Doxorubicin / Q000627:therapeutic use; D007887:Fabaceae / Q000737:chemistry*; D005260:Female; D007531:Isoflurophate / Q000627:therapeutic use; D008727:Methotrexate / Q000627:therapeutic use; D008970:Molecular Weight; D009363:Neoplasm Proteins / Q000037:antagonists & inhibitors / Q000302:isolation & purification; D009368:Neoplasm Transplantation; D008517:Phytotherapy; D010946:Plants, Medicinal; D051381:Rats; D017208:Rats, Wistar; D012517:Sarcoma, Yoshida / Q000188:drug therapy* / Q000201:enzymology; D012697:Serine Endopeptidases / Q000302:isolation & purification; D015842:Serine Proteinase Inhibitors / Q000627:therapeutic use*; D013347:Subcellular Fractions / Q000201:enzymology
D000972:Antineoplastic Agents, Phytogenic; D009363:Neoplasm Proteins; D015842:Serine Proteinase Inhibitors; D007531:Isoflurophate; D004317:Doxorubicin; D003520:Cyclophosphamide; D012697:Serine Endopeptidases; D008727:Methotrexate